[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Enveda Therapeutics\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":88},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,64],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100642106","phase-2-a-phase-2b-dose-ranging-study-to-evaluate-the-efficacy-and-safety-of-env-294-in-adults-with-moderate-to-severe-atopic-dermatitis-100642106",false,"NCT07643766","A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis","A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adult Participants With Moderate-to-Severe Atopic Dermatitis","Inclusion Criteria:\n\nIn order to participate in this study all participants must:\n\n1. Be at least 18 years of age at the time of signing the ICF.\n2. Have chronic AD (also known as atopic eczema) that was diagnosed at least 12 months prior to Screening.\n3. Have a history of inadequate response or intolerance to topical corticosteroids or other topical treatments for AD within 6 months before Screening and\u002For inadequate response to a systemic therapy within 12 months before Screening.\n4. Have moderate-to-severe AD, at Screening and Baseline, as defined by the following criteria:\n\n   1. A vIGA score of 3 (moderate) or 4 (severe)\n   2. EASI score of ≥16\n   3. Body surface area involvement of ≥10%\n5. Have PP-NRS score ≥4 Screening and Baseline - the baseline score refers to a weekly average.\n6. Use a bland emollient daily for at least 1 week prior to Day 1 and agree to continue using that same emollient daily at the same frequency (minimally, once daily) throughout the study.\n7. Participants of reproductive potential (male and female participants) must practice effective methods of contraception as per protocol.\n\nExclusion Criteria:\n\nParticipants are excluded if they:\n\n1. Have any clinically significant medical condition or physical\u002Flaboratory\u002FECG\u002Fvital signs abnormality that would, in the opinion of the investigator, put the participant at undue risk or interfere with interpretation of study results.\n2. Have clinically significant abnormalities in any of the clinical laboratory evaluations at Screening or Baseline as determined by the Investigator.\n3. Have the presence of any concomitant skin conditions (eg, psoriasis, seborrheic dermatitis) or have large tattoos that would interfere with clinical assessment, evaluation of AD, or treatment response as determined by the investigator.\n4. Have an ongoing clinically significant skin infection or is receiving treatment for infection that may interfere with assessment of AD as determined by the investigator.\n5. Are pregnant or breastfeeding or are planning to become pregnant during the duration of the study and for 90 days after the last administration of study drug.\n6. Are taking or have taken any prespecified prohibited therapies within a specific timeframe as determined by the Investigator.","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This double-blind, placebo-controlled study is designed to evaluate the safety and efficacy of ENV-294 in adults with moderate-to-severe atopic dermatitis (AD). The study will compare three dose levels of ENV-294 with placebo administered for 12 weeks. Participants will undergo screening, receive study treatment, and complete scheduled assessments of disease activity, symptoms, quality of life, safety, pharmacokinetics, and biomarker responses.",[26],"Atopic Dermatitis","NOT_YET_RECRUITING","2026-06-07",{"date":30,"type":31},"2026-06-12","ACTUAL",{"date":33,"type":20},"2026-06",{"date":35,"type":20},"2028-05",{"name":37,"class":38},"Enveda Therapeutics","INDUSTRY",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100615883","phase-2-study-of-env-294-in-adults-with-moderate-to-severe-atopic-dermatitis-100615883","NCT07298395","Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis","A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ENV-294 in Adult Participants With Moderate-to-Severe Atopic Dermatitis","Inclusion Criteria:\n\n* Have chronic atopic dermatitis that was diagnosed at least 12 months prior to the first study visit\n* Have moderate-to-severe AD at screening and baseline as defined by the following criteria:\n\n  * A vIGA score of 3 (moderate) or 4 (severe)\n  * EASI score of ≥16\n  * BSA ≥10%\n  * PP-NRS score of ≥4\n* Have had either a poor response or intolerance to topical treatments for atopic dermatitis (such as corticosteroids) within the past 6 months\n* Use a bland moisturizer at least daily\n\nExclusion Criteria:\n\n* Current or recurrent medical conditions that could affect the study drug or study assessments\n* Any illness that could impact participant safety or active infections\n* Ongoing skin condition or large tattoos that would interfere with clinical assessment\n* Clinically significant skin infection requiring treatment\n* Clinically significant abnormal laboratory assessments at screening","75 Years",{"count":49,"type":20},60,[23],"The goal of this clinical trial is to learn about the safety and effectiveness of ENV-294 in adults with moderate to severe atopic dermatitis.\n\nThe main questions it will answer are:\n\n* Is there an impact on the severity and area of atopic dermatitis when participants take ENV-294\n* What medical problems do participants have when taking ENV-294\n\nParticipants will:\n\n* Take drug ENV-294 or a placebo once every day for 12 weeks\n* Visit the clinic every 2 to 4 weeks for checkups and tests\n* Keep a diary of their symptoms and when they took their study drug\n* Return to the clinic for the final study visit at approximately week 16",[53],"Atopic Dermatitis (AD)","RECRUITING","2026-06-02",{"date":57,"type":31},"2026-06-04",{"date":59,"type":31},"2025-12-22",{"date":61,"type":20},"2026-12",{"name":37,"class":38},23,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":47,"enrollmentInfo":71,"targetDuration":4,"studyType":21,"phases":73,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},"100616103","phase-2-env-294-for-moderate-to-severe-asthma-a-12-week-study-in-adults-100616103","NCT07301255","ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults","A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ENV-294 in Adult Participants With Moderate-to-Severe Asthma","Inclusion Criteria:\n\n* Able to read, understand, and sign an informed consent form before any study procedures\n* Male or female adults aged 18 to 75 years with a physician diagnosis of moderate to severe asthma for at least 12 months\n* Receiving stable treatment with an inhaled corticosteroid (ICS) plus a long-acting beta₂-agonist (LABA) for at least 2 months before screening\n* Pre-bronchodilator FEV₁ between 50% and 80% of predicted normal at screening and baseline\n* Demonstrated bronchodilator reversibility\n* ACQ-5 score ≥1.25 to ≤3.0 at screening and baseline\n* History of at least one asthma exacerbation in the past 12 months requiring systemic corticosteroids or hospitalization\u002Femergency care\n\nExclusion Criteria:\n\n* Recent moderate or severe asthma exacerbation (within 4 weeks before screening)\n* History of life-threatening asthma\n* Other significant pulmonary disease\n* Recent bronchial thermoplasty (within 2 years)\n* Uncontrolled current or recurrent concomitant illness\n* Recent use of biologic therapies for asthma (within 6 months or 5 half-lives)\n* Require immunosuppressive medications or frequent systemic corticosteroids\n* Current smokers or former smokers with significant smoking history\n* Uncontrolled hypertension\n* Significant hepatic impairment",{"count":72,"type":20},50,[23],"This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and potential efficacy of ENV-294 in adults with moderate to severe asthma who are receiving background treatment with inhaled corticosteroids (ICS) and long-acting beta₂-agonists (LABA).\n\nParticipants will take oral ENV-294 or placebo once daily for 12 weeks. The study includes a screening period of up to 28 days before randomization to confirm eligibility. Study visits and assessments will be conducted to monitor safety, measure drug levels in the blood, and evaluate effects on asthma control and lung function.",[76],"Asthma",[78],"Asthma in Adults","2026-04-20",{"date":81,"type":31},"2026-04-23",{"date":83,"type":31},"2026-01-09",{"date":85,"type":20},"2027-01",{"name":37,"class":38},14,""]